Product Information
ARNUITY ELLIPTA 200 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $8.9036 per EA under NDC 00173087610. Its NADAC has been published 585 times since Jul 22, 2015.
FDA first approved this application on Aug 20, 2014.
Strength
200 ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173087610
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
FLUTICASONE FUROATEApproval Type
New Drug (NDA)
FDA Application
NDA205625FDA Approved
8/20/2014
On Market Since
8/20/2014
Pharmacological Classes
Price Statistics
The NADAC for ARNUITY ELLIPTA 200 MCG INH has been published 585 times since Jul 22, 2015, and over the history we have for it it has risen 59.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.9036 per EA |
|---|---|
| All-time high | $8.9289 (Sep 11, 2024) |
| All-time low | $5.5881 (Jul 22, 2015) |
| 52-week high | $8.9100 |
| 52-week low | $8.8941 |
| Median price | $7.8673 |
| Average price | $7.8359 |
| Largest weekly change | +8.5% (Dec 30, 2015) |
| Weeks tracked | 585 |
| Tracking since | Jul 22, 2015 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 36% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
fluticasone furoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARNUITY ELLIPTA 200 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for ARNUITY ELLIPTA 200 MCG INH, manufactured by GlaxoSmithKline LLC, is $8.9036 per EA (NDC 00173087610), effective Sep 30, 2026.
How has the price of ARNUITY ELLIPTA 200 MCG INH changed over time?
Over the history we have for it, the NADAC for ARNUITY ELLIPTA 200 MCG INH has risen 59.3%. It has been tracked across 585 weekly CMS publications since Jul 22, 2015.
What are the highest and lowest recorded NADAC prices for ARNUITY ELLIPTA 200 MCG INH?
Since Jul 22, 2015, the NADAC for ARNUITY ELLIPTA 200 MCG INH has ranged from a low of $5.5881 (Jul 22, 2015) to a high of $8.9289 (Sep 11, 2024), with a median of $7.8673 per EA.
Are there cheaper alternatives to ARNUITY ELLIPTA 200 MCG INH?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, FLUTICASONE ELLIPTA 200 MCG INH, is $5.7140 per EA — about 36% below ARNUITY ELLIPTA 200 MCG INH.
Who manufactures ARNUITY ELLIPTA 200 MCG INH?
ARNUITY ELLIPTA 200 MCG INH (NDC 00173087610) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.